Please use this identifier to cite or link to this item:
|Title:||Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors|
|Authors:||Lydia W.T. Cheung|
Patrick K.S. Ng
David H. Hawke
Russell R. Broaddus
Gordon B. Mills
University of Texas MD Anderson Cancer Center
|Keywords:||Biochemistry, Genetics and Molecular Biology;Medicine|
|Citation:||Cancer Cell. Vol.26, No.4 (2014), 479-494|
|Abstract:||© 2014 Elsevier Inc. PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1R348*and a nearby mutation PIK3R1L370fs, in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK and JNK inhibitors invitro and invivo. Consistent with the response to inhibitors, PIK3R1R348*and PIK3R1L370fsunexpectedly increase JNK and ERK phosphorylation. Surprisingly, p85α R348*and L370fs localize to the nucleus where the mutants provide a scaffold for multiple JNK pathway components facilitating nuclear JNK pathway activation. Our findings uncover an unexpected neomorphic role for PIK3R1R348*and neighboring truncation mutations in cellular signaling, providing a rationale for therapeutic targeting of these mutant tumors.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.